FDA Panel To Assess Excessive Sedation Linked To Lilly’s Zyprexa Depot Formulation

FDA Psychopharmacologic Drugs Advisory Committee will vote Feb. 6 on the safety and efficacy of the long-acting atypical antipsychotic.